155 related articles for article (PubMed ID: 12190294)
1. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Favaloro EJ; Orsag I; Bukuya M; McDonald D
Pathology; 2002 Aug; 34(4):348-55. PubMed ID: 12190294
[TBL] [Abstract][Full Text] [Related]
2. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
3. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Baig MA
Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
6. Laboratory Testing for Activated Protein C Resistance (APCR).
Mohammed S; Favaloro EJ
Methods Mol Biol; 2017; 1646():137-143. PubMed ID: 28804824
[TBL] [Abstract][Full Text] [Related]
7. Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods.
Maryamchik E; Van Cott EM
Arch Pathol Lab Med; 2020 Nov; 144(11):1401-1407. PubMed ID: 32101451
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Guerrero F; Arnaud C; Nguyen F; Boneu B; Sié P
Thromb Haemost; 2006 Apr; 95(4):728-34. PubMed ID: 16601846
[TBL] [Abstract][Full Text] [Related]
9. Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene "Mutation" (G20210A).
Favaloro EJ
Semin Thromb Hemost; 2019 Oct; 45(7):730-742. PubMed ID: 31398733
[TBL] [Abstract][Full Text] [Related]
10. Danger of false negative (exclusion) or false positive (diagnosis) for 'congenital thrombophilia' in the age of anticoagulants.
Favaloro EJ
Clin Chem Lab Med; 2019 May; 57(6):873-882. PubMed ID: 30485173
[TBL] [Abstract][Full Text] [Related]
11. The association between activated protein C ratio and Factor V Leiden are gender-dependent.
Hansen RS; Nybo M
Clin Chem Lab Med; 2019 Jul; 57(8):1229-1234. PubMed ID: 30903752
[TBL] [Abstract][Full Text] [Related]
12. Laboratory diagnosis of hereditary thrombophilia.
Michiels JJ; Hamulyák K
Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
[TBL] [Abstract][Full Text] [Related]
13. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban Causes Missed Diagnosis of Protein S Deficiency but Not of Activated Protein C Resistance (Factor V Leiden).
Maryamchik E; Rosenbaum MW; Van Cott EM
Arch Pathol Lab Med; 2018 Jan; 142(1):70-74. PubMed ID: 28920711
[TBL] [Abstract][Full Text] [Related]
15. APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
Sedano-Balbás S; Lyons M; Cleary B; Murray M; Gaffney G; Maher M
BMC Pregnancy Childbirth; 2010 Mar; 10():11. PubMed ID: 20214832
[TBL] [Abstract][Full Text] [Related]
16. Laboratory Testing for Activated Protein C Resistance (APCR): An Update.
Favaloro EJ; Mohammed S; Vong R; Pasalic L
Methods Mol Biol; 2023; 2663():203-210. PubMed ID: 37204711
[TBL] [Abstract][Full Text] [Related]
17. [National evaluation of the diagnosis of activated protein C resistance].
Montiel-Manzano G; de la Peña-Díaz A; Majluf-Cruz A; Cesarman-Maus G; Corona-de la Peña N; Cruz-Cruz D; Gaminio E; Martínez-Murillo C; Mayagoitia T; Miranda-Peralta E; Poblete T; Quintana-Martínez S; Ramírez R; Razo D; Ruiz de Chávez-Ochoa A; Reyes-Núñez VA; Salazar R; Vicencio-Santiago GV; Villa R
Rev Invest Clin; 2003; 55(3):358-69. PubMed ID: 14515684
[TBL] [Abstract][Full Text] [Related]
18. Activated protein C resistance: the influence of ABO-blood group, gender and age.
Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L
Thromb Res; 2006; 117(6):665-70. PubMed ID: 16023702
[TBL] [Abstract][Full Text] [Related]
19. Comparison of an activated partial thromboplastin time with a Russell viper venom time test in screening for factor V(Leiden) (FVR506Q).
Sweeney JD; Blair AJ; King TC
Am J Clin Pathol; 1997 Jul; 108(1):74-7. PubMed ID: 9208981
[TBL] [Abstract][Full Text] [Related]
20. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
